Abeona Therapeutics (ABEO) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 38.4% versus a loss of 46.0%. Over five years, ORMP leads with a -82.3% price change compared with -86.7% for ABEO. Abeona Therapeutics is the larger company by market cap ($165.3 million vs $155.2 million), about 1.1 times the size.
Oramed Pharmaceuticals converts more of its revenue into profit, with a net margin of 3202.5% versus 1223.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | ORMP |
|---|---|---|
| Share price | $2.42 | $3.57 |
| Market cap | $165.31M | $155.24M |
| 1-day change | -1.22% | -3.25% |
| YTD return | -54.08% | +25.26% |
| 1-year return | -45.98% | +38.37% |
| 5-year return | -86.74% | -82.34% |
| P/E ratio (TTM) | — | 1.05 |
| EPS (TTM) | $-1.16 | $3.41 |
| Dividend yield | 0.00% | 7.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | $2.00M |
| Net income (latest FY) | $71.18M | $64.05M |
| Gross margin | 73.68% | 0.65% |
| Operating margin | -1536.91% | -754.40% |
| Net margin | 1223.08% | 3202.50% |
| 52-week high | $7.65 | $5.47 |
| 52-week low | $2.09 | $2.52 |
| Distance from 52-week high | -68.37% | -34.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +542.98% | +96.08% |
| Average volume | 1.66M | 173.38K |
| Shares outstanding | 68.31M | 43.49M |
| Employees | 226 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed ABEO by 84.4 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).
- Oramed Pharmaceuticals is more profitable, keeping 3202.5 cents of every revenue dollar as net income versus 1223.1 cents for Abeona Therapeutics.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
ABEO vs ORMP FAQ
Which is bigger, Abeona Therapeutics or Oramed Pharmaceuticals?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $165.31M compared with $155.24M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, ABEO or ORMP?
ORMP returned +38.37% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Abeona Therapeutics or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 7.00%, while Abeona Therapeutics does not currently pay a regular dividend.
Are Abeona Therapeutics and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.